PMC:7795856 / 1102-1341 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"35","span":{"begin":4,"end":19},"obj":"Disease"}],"attributes":[{"id":"A35","pred":"tao:has_database_id","subj":"35","obj":"MESH:D007674"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" to retarded kidney filtration. Our study provides the basis for therapeutic development of a next generation thymosin α1 with prolonged circulation. Generally, the strategy of producing an N-terminally protected PASylated peptide solves t"}

{"project":"LitCovid-sentences","denotations":[{"id":"T10","span":{"begin":32,"end":149},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":" to retarded kidney filtration. Our study provides the basis for therapeutic development of a next generation thymosin α1 with prolonged circulation. Generally, the strategy of producing an N-terminally protected PASylated peptide solves t"}